NRx Pharmaceuticals, Inc. (NRXP)
Largest Insider Buys in Sector
NRXP Stock Price History Chart
NRXP Stock Performance
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and …
Insider Activity of NRx Pharmaceuticals, Inc.
Over the last 12 months, insiders at NRx Pharmaceuticals, Inc. have bought $0 and sold $0 worth of NRx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at NRx Pharmaceuticals, Inc. have bought $409,877 and sold $686,775 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 70,000 shares for transaction amount of $20,125 was made by Hurvitz Chaim (director) on 2023‑08‑30.
List of Insider Buy and Sell Transactions, NRx Pharmaceuticals, Inc.
| 2023-08-30 | director | 70,000 0.0777% | $0.29 | $20,125 | +4.57% | |||
| 2023-08-30 | director | 35,000 0.0432% | $0.32 | $11,197 | +4.57% | |||
| 2023-08-23 | Chief Scientist | 100,000 0.135% | $0.33 | $33,000 | +16.90% | |||
| 2023-08-22 | Chief Scientist | 200,000 0.2614% | $0.32 | $64,400 | +9.93% | |||
| 2022-12-16 | CHIEF EXECUTIVE OFFICER | 50,000 0.0773% | $1.17 | $58,500 | -55.52% | |||
| 2022-12-16 | CHIEF FINANCIAL OFFICER | 30,000 0.0436% | $1.10 | $33,000 | -55.52% | |||
| 2022-12-07 | Sale | director | 400,000 0.4224% | $1.00 | $400,000 | -63.19% | ||
| 2022-11-30 | Sale | director | 8,441 0.0134% | $1.50 | $12,700 | -60.42% | ||
| 2022-11-29 | Sale | director | 13,730 0.0228% | $1.50 | $20,651 | -58.70% | ||
| 2022-11-28 | director | 6,750 0.0102% | $1.25 | $8,413 | -54.32% | |||
| 2022-11-25 | CHIEF FINANCIAL OFFICER | 16,337 0.0241% | $1.11 | $18,215 | -49.65% | |||
| 2022-11-18 | director | 40,408 0.0593% | $1.10 | $44,449 | -47.89% | |||
| 2022-11-17 | Sale | director | 33,018 0.0433% | $1.05 | $34,745 | -51.07% | ||
| 2022-11-17 | director | 171,780 0.2312% | $1.08 | $185,522 | -51.07% | |||
| 2022-11-16 | Sale | director | 133,719 0.1975% | $1.02 | $136,393 | -42.86% | ||
| 2022-11-16 | director | 287,812 0.4126% | $0.99 | $284,934 | -42.86% | |||
| 2022-11-11 | Sale | director | 49,200 0.0753% | $1.01 | $49,510 | -38.75% | ||
| 2022-07-29 | Sale | 784,063 1.5019% | $1.01 | $791,433 | -6.94% | |||
| 2022-06-03 | Sale | 115,657 0.1594% | $0.67 | $76,947 | +0.54% | |||
| 2022-06-01 | Chief Scientist | 100,000 0.1543% | $0.58 | $58,000 | +29.02% |
Insider Historical Profitability
| Hurvitz Chaim | director | 570000 5.3026% | $1.32 | 4 | 0 | <0.0001% |
| Javitt Jonathan C | Chief Scientist | 446332 4.1521% | $1.32 | 3 | 1 | +29.02% |
| ACKERMAN RICHARD | President and CEO | 225000 2.0931% | $1.32 | 1 | 1 | |
| Gorovitz Aaron | director | 105000 0.9768% | $1.32 | 1 | 0 | |
| Willard Stephen H | CHIEF EXECUTIVE OFFICER | 50000 0.4651% | $1.32 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $679.56M | 13.46 | 1.44M | -0.35% | -$2.42M | 0.01 | |
| AdvisorShares | $290.12M | 5.75 | 614,793 | -4.33% | -$13.14M | 20.87 | |
| Geode Capital Management | $198.24M | 3.93 | 419,954 | +1.95% | +$3.79M | 0.02 | |
| BlackRock | $137.19M | 2.72 | 290,714 | 0% | +$0 | <0.01 | |
| Renaissance Technologies | $89,000.00 | 1.76 | 188,780 | -5.84% | -$5,515.94 | <0.0001 |